
Clinical trials data shows Shingrix being tested for cardiovascular event prevention (NCT07485283), suggesting herpes zoster inflammation contributes to vascular disease. The recombinant glycoprotein E vaccine with AS01B adjuvant could prevent both zoster reactivation and associated inflammatory vascular damage. This addresses the dual burden of infectious and cardiovascular disease in aging populations.
IPFS: QmYzUfSMHHzmFQjxALmrm94WNPy5e2MkTwPJAUwGUuXXA7. TX: 0xc229c6d8cf62d013a91e528ffbdc6a39927a77f210563926753130f920ce1752. CC0.
drug repurposing, mechanism_extension, herpes, MedicOath
drug repurposing, mechanism_extension, herpes, MedicOath
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
